John E. Pak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John E. Pak has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Eric Waltari
Chan Zuckerberg Biohub San Francisco, San Francisco, CA, USA
6 shared publications - Wesley Wu
Chan Zuckerberg Biohub, San Francisco, USA
4 shared publications - Joseph L. DeRisi
Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, USA
3 shared publications Nash L. Bulaong
Chan Zuckerberg Biohub, San Francisco, USA
3 shared publications- Bryan Greenhouse
Department of Medicine, University of California, San Francisco, USA
2 shared publications - Caryn Bern
Department of Epidemiology and Biostatistics, University of California San Francisco School of Medicine , San Francisco, CA 94143
2 shared publications
Latest Publications
- Open Access
Proteome-scale inference of transcription factor binding motifs from predicted protein-DNA structures
Transcription factors (TFs) control development and cell identity by binding sequence-specific DNA motifs, yet the binding specificities of most TFs remain unknown because experimental binding assays do not scale. In zebrafish, only one-third of TFs have assigned motifs, nearly all inferred by homology from human or mouse experimental data. Here we present a proteome-scale computational screen that infers DNA-binding specificity from predicted protein-DNA structures. We use AlphaFold3 to model zebrafish TFs with candidate motif sequences derived from accessible chromatin, then use NA-MPNN to infer the DNA motifs from the most confident predictions. Across 210 TFs with experimentally characterized orthologs, predicted motifs match the known motif for 44%. Propagated through sequence clusters, these predictions form ZebraMotif, a motif database for all 2,543 zebrafish TFs. ZebraMotif covers 2.8 times as many TFs as CisBP's zebrafish collection and links accessible regulatory elements to candidate upstream regulators genome-wide. Because the approach requires only a proteome and a set of candidate motifs, it is applicable to any species lacking experimental binding data.
Open AccessProteome-scale inference of transcription factor binding motifs from predicted protein-DNA structures
Transcription factors (TFs) control development and cell identity by binding sequence-specific DNA motifs, yet the binding specificities of most TFs remain unknown because experimental binding assays do not scale. In zebrafish, only one-third of TFs have assigned motifs, nearly all inferred by homology from human or mouse experimental data. Here we present a proteome-scale computational screen that infers DNA-binding specificity from predicted protein-DNA structures. We use AlphaFold3 to model zebrafish TFs with candidate motif sequences derived from accessible chromatin, then use NA-MPNN to infer the DNA motifs from the most confident predictions. Across 210 TFs with experimentally characterized orthologs, predicted motifs match the known motif for 44%. Propagated through sequence clusters, these predictions form ZebraMotif, a motif database for all 2,543 zebrafish TFs. ZebraMotif covers 2.8 times as many TFs as CisBP's zebrafish collection and links accessible regulatory elements to candidate upstream regulators genome-wide. Because the approach requires only a proteome and a set of candidate motifs, it is applicable to any species lacking experimental binding data.
- Top Cited PapersOpen Access
Language Modeling Materializes a World Model of Protein Biology
Proteins are fundamental to life. The full extent of their biology is beyond our ability to characterize with experimental approaches in the physical laboratory. Accurate digital representations could accelerate the discovery of protein biology through virtual experiments. We propose language modeling to learn unified and general representations that can be scaled to all of protein biology. Building on these representations, we develop a structure prediction model that exceeds the performance of established methods for biomolecular complex prediction across benchmarks, including for the interactions of antibodies with their targets. A simple search procedure yields high experimental success rates for the discovery of proteins with nanomolar binding affinities for both miniproteins and single-chain antibodies, a modality critical for therapeutic design. Study of the concepts in the language model's representation space reveals a systematic organization aligned with the reductionist understanding of proteins developed through empirical science. Leveraging this organization, we generate a comprehensive map of protein biology encompassing over 6.8 billion sequences and 1.1 billion predicted structures, identifying connections across known and unknown biology. As a whole, this shows language modeling as a powerful substrate for representing the biology of proteins, operating across scales from the prediction and design of protein interactions at the atomic level, to identifying properties of proteins at different levels of granularity and abstraction, to the scale of mapping connections between proteins across billions of years of evolution.
Top Cited PapersOpen AccessLanguage Modeling Materializes a World Model of Protein Biology
Proteins are fundamental to life. The full extent of their biology is beyond our ability to characterize with experimental approaches in the physical laboratory. Accurate digital representations could accelerate the discovery of protein biology through virtual experiments. We propose language modeling to learn unified and general representations that can be scaled to all of protein biology. Building on these representations, we develop a structure prediction model that exceeds the performance of established methods for biomolecular complex prediction across benchmarks, including for the interactions of antibodies with their targets. A simple search procedure yields high experimental success rates for the discovery of proteins with nanomolar binding affinities for both miniproteins and single-chain antibodies, a modality critical for therapeutic design. Study of the concepts in the language model's representation space reveals a systematic organization aligned with the reductionist understanding of proteins developed through empirical science. Leveraging this organization, we generate a comprehensive map of protein biology encompassing over 6.8 billion sequences and 1.1 billion predicted structures, identifying connections across known and unknown biology. As a whole, this shows language modeling as a powerful substrate for representing the biology of proteins, operating across scales from the prediction and design of protein interactions at the atomic level, to identifying properties of proteins at different levels of granularity and abstraction, to the scale of mapping connections between proteins across billions of years of evolution.
- Open Access
- 20 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (12) , eadx5178
Conformational dynamics of SARS-CoV-2 spike on a membrane reveals the allosteric effects of furin cleavage and the D614G mutation
By combining hydrogen-deuterium exchange monitored by mass spectrometry (HDX-MS) with the ability of enveloped virus–like particles (eVLPs) to display full-length native-like severe acute respiratory syndrome coronavirus 2 spike protein, we have determined the energetic and conformational effects of both the membrane environment and unique sequence features that are considered incompatible with soluble protein constructs. We find that eVLP-displayed spike can sample the open-interface trimer conformation observed in soluble constructs of spike, including sequences from engineered vaccine constructs and native viral sequences inaccessible to studies on soluble constructs. Moreover, the D614G mutation, which arose early in the pandemic, favors the canonical “closed-interface” prefusion conformation, potentially mitigating premature S1 shedding in the presence of a cleaved furin site and providing an evolutionary advantage to the virus. Furin cleavage at the S1/S2 boundary allosterically increases the flexibility of the S2′ site, which may facilitate increased TMPRSS2 processing, enhancing viral infectivity. The use of eVLPs in HDX-MS studies provides a powerful platform for studying viral and membrane proteins in near-native environments.
- 20 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (12) , eadx5178
Open AccessConformational dynamics of SARS-CoV-2 spike on a membrane reveals the allosteric effects of furin cleavage and the D614G mutation
By combining hydrogen-deuterium exchange monitored by mass spectrometry (HDX-MS) with the ability of enveloped virus–like particles (eVLPs) to display full-length native-like severe acute respiratory syndrome coronavirus 2 spike protein, we have determined the energetic and conformational effects of both the membrane environment and unique sequence features that are considered incompatible with soluble protein constructs. We find that eVLP-displayed spike can sample the open-interface trimer conformation observed in soluble constructs of spike, including sequences from engineered vaccine constructs and native viral sequences inaccessible to studies on soluble constructs. Moreover, the D614G mutation, which arose early in the pandemic, favors the canonical “closed-interface” prefusion conformation, potentially mitigating premature S1 shedding in the presence of a cleaved furin site and providing an evolutionary advantage to the virus. Furin cleavage at the S1/S2 boundary allosterically increases the flexibility of the S2′ site, which may facilitate increased TMPRSS2 processing, enhancing viral infectivity. The use of eVLPs in HDX-MS studies provides a powerful platform for studying viral and membrane proteins in near-native environments.
- Open Access
- 5 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
A Trypanosoma cruzi trans-sialidase peptide demonstrates high serological prevalence among infected populations across endemic regions
BACKGROUND: Infection by Trypanosoma cruzi , the agent of Chagas disease, is endemic to the Americas and can irreparably damage the cardiac and gastrointestinal systems during decades of parasite persistence. Diagnosis of chronic infection requires confirmation by multiple serological assays due to the imperfect performance of existing tests. Current serology tests were developed using small specimen sets predominantly from South America, and lower performance has been observed in patients who acquired infection in Central America and Mexico. METHODS: To improve Chagas disease serology, we evaluated antibody responses against the entire T . cruzi proteome with phage display immunoprecipitation sequencing and further evaluated high-prevalence antigens by immunoassay. We utilized specimen sets representing Mexico, Central America, and South America and varying cardiac disease presentations, from 185 cases and 143 controls. RESULTS: We identified over 1,300 antigenic T . cruzi peptides. A trans-sialidase antigen demonstrated high seroprevalence across all regions and has not previously been described as a diagnostic target to our knowledge. Orthogonal validation of this peptide demonstrated increased antibody reactivity for infections originating from Central America. CONCLUSION: This study provides proteome-wide identification of seroreactive T . cruzi peptides across a range of endemic populations not previously represented in antigen discovery and identifies a trans-sialidase peptide antigen (TS23) with potential for translation into diagnostic serological assays. FUNDING: Chan Zuckerberg Biohub, the Chan Zuckerberg Biohub Physician-Scientist Fellowship Program, the NIH National Heart Lung and Blood Institute award K38HL154203, and the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development award F30HD117526.
- 5 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
Open AccessA Trypanosoma cruzi trans-sialidase peptide demonstrates high serological prevalence among infected populations across endemic regions
BACKGROUND: Infection by Trypanosoma cruzi , the agent of Chagas disease, is endemic to the Americas and can irreparably damage the cardiac and gastrointestinal systems during decades of parasite persistence. Diagnosis of chronic infection requires confirmation by multiple serological assays due to the imperfect performance of existing tests. Current serology tests were developed using small specimen sets predominantly from South America, and lower performance has been observed in patients who acquired infection in Central America and Mexico. METHODS: To improve Chagas disease serology, we evaluated antibody responses against the entire T . cruzi proteome with phage display immunoprecipitation sequencing and further evaluated high-prevalence antigens by immunoassay. We utilized specimen sets representing Mexico, Central America, and South America and varying cardiac disease presentations, from 185 cases and 143 controls. RESULTS: We identified over 1,300 antigenic T . cruzi peptides. A trans-sialidase antigen demonstrated high seroprevalence across all regions and has not previously been described as a diagnostic target to our knowledge. Orthogonal validation of this peptide demonstrated increased antibody reactivity for infections originating from Central America. CONCLUSION: This study provides proteome-wide identification of seroreactive T . cruzi peptides across a range of endemic populations not previously represented in antigen discovery and identifies a trans-sialidase peptide antigen (TS23) with potential for translation into diagnostic serological assays. FUNDING: Chan Zuckerberg Biohub, the Chan Zuckerberg Biohub Physician-Scientist Fellowship Program, the NIH National Heart Lung and Blood Institute award K38HL154203, and the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development award F30HD117526.
- Top Cited Papers
- 29 July 2025
- Published by Springer Nature in Nature
- p. 1-3
The Virtual Lab of AI agents designs new SARS-CoV-2 nanobodies
Science frequently benefits from teams of interdisciplinary researchers1–3, but many scientists do not have easy access to experts from multiple fields4,5. While large language models (LLMs) have shown an impressive ability to aid researchers across diverse domains, their uses have been largely limited to answering specific scientific questions rather than performing open-ended research6–11. Here, we expand the capabilities of LLMs for science by introducing the Virtual Lab, an AI-human research collaboration to perform sophisticated, interdisciplinary science research. The Virtual Lab consists of an LLM principal investigator agent guiding a team of LLM scientist agents through a series of research meetings, with a human researcher providing high-level feedback. We apply the Virtual Lab to design nanobody binders to recent variants of SARS-CoV-2. The Virtual Lab creates a novel computational nanobody design pipeline that incorporates ESM, AlphaFold-Multimer, and Rosetta and designs 92 new nanobodies. Experimental validation reveals a range of functional nanobodies with promising binding profiles across SARS-CoV-2 variants. In particular, two new nanobodies exhibit improved binding to the recent JN.1 or KP.3 variants12,13 while maintaining strong binding to the ancestral viral spike protein, suggesting exciting candidates for further investigation. This demonstrates how the Virtual Lab can rapidly make an impactful, real-world scientific discovery.
- 29 July 2025
- Published by Springer Nature in Nature
- p. 1-3
Top Cited PapersThe Virtual Lab of AI agents designs new SARS-CoV-2 nanobodies
Science frequently benefits from teams of interdisciplinary researchers1–3, but many scientists do not have easy access to experts from multiple fields4,5. While large language models (LLMs) have shown an impressive ability to aid researchers across diverse domains, their uses have been largely limited to answering specific scientific questions rather than performing open-ended research6–11. Here, we expand the capabilities of LLMs for science by introducing the Virtual Lab, an AI-human research collaboration to perform sophisticated, interdisciplinary science research. The Virtual Lab consists of an LLM principal investigator agent guiding a team of LLM scientist agents through a series of research meetings, with a human researcher providing high-level feedback. We apply the Virtual Lab to design nanobody binders to recent variants of SARS-CoV-2. The Virtual Lab creates a novel computational nanobody design pipeline that incorporates ESM, AlphaFold-Multimer, and Rosetta and designs 92 new nanobodies. Experimental validation reveals a range of functional nanobodies with promising binding profiles across SARS-CoV-2 variants. In particular, two new nanobodies exhibit improved binding to the recent JN.1 or KP.3 variants12,13 while maintaining strong binding to the ancestral viral spike protein, suggesting exciting candidates for further investigation. This demonstrates how the Virtual Lab can rapidly make an impactful, real-world scientific discovery.
- Open Access
The Interplay of Furin Cleavage and D614G in Modulating SARS-CoV-2 Spike Protein Dynamics
Summary: We report a detailed analysis of the full-length SARS-CoV-2 spike dynamics within a native-like membrane environment and variants inaccessible to studies on soluble constructs by conducting hydrogen-deuterium exchange mass spectrometry (HDX-MS) on enveloped virus-like particles (eVLPs) displaying various spike constructs. We find that the previously identified open-interface trimer conformation is sampled in all eVLP-displayed spike variants studied including sequences from engineered vaccine constructs and native viral sequences. The D614G mutation, which arose early in the pandemic, favors the canonical ‘closed-interface’ prefusion conformation, potentially mitigating premature S1 shedding in the presence of a cleaved furin site and providing an evolutionary advantage to the virus. Remarkably, furin cleavage at the S1/S2 boundary allosterically increases the flexibility of the S2’ site, which may facilitate increased TMPRSS2 processing, enhancing viral infectivity. The use of eVLPs in HDX-MS studies provides a powerful platform for studying viral and membrane proteins in near-native environments.
Open AccessThe Interplay of Furin Cleavage and D614G in Modulating SARS-CoV-2 Spike Protein Dynamics
Summary: We report a detailed analysis of the full-length SARS-CoV-2 spike dynamics within a native-like membrane environment and variants inaccessible to studies on soluble constructs by conducting hydrogen-deuterium exchange mass spectrometry (HDX-MS) on enveloped virus-like particles (eVLPs) displaying various spike constructs. We find that the previously identified open-interface trimer conformation is sampled in all eVLP-displayed spike variants studied including sequences from engineered vaccine constructs and native viral sequences. The D614G mutation, which arose early in the pandemic, favors the canonical ‘closed-interface’ prefusion conformation, potentially mitigating premature S1 shedding in the presence of a cleaved furin site and providing an evolutionary advantage to the virus. Remarkably, furin cleavage at the S1/S2 boundary allosterically increases the flexibility of the S2’ site, which may facilitate increased TMPRSS2 processing, enhancing viral infectivity. The use of eVLPs in HDX-MS studies provides a powerful platform for studying viral and membrane proteins in near-native environments.
- Open Access
A Trypanosoma cruzi Trans-Sialidase Peptide Demonstrates High Serological Prevalence Among Infected Populations Across Endemic Regions of Latin America
Infection by Trypanosoma cruzi , the agent of Chagas disease, can irreparably damage the cardiac and gastrointestinal systems during decades of parasite persistence and related inflammation in these tissues. Diagnosis of chronic disease requires confirmation by multiple serological assays due to the imperfect performance of existing clinical tests. Current serology tests utilize antigens discovered over three decades ago with small specimen sets predominantly from South America, and lower test performance has been observed in patients who acquired T. cruzi infection in Central America and Mexico. Here, we attempt to address this gap by evaluating antibody responses against the entire T. cruzi proteome with phage display immunoprecipitation sequencing comprised of 228,127 47-amino acid peptides. We utilized diverse specimen sets from Mexico, Central America and South America, as well as different stages of cardiac disease severity, from 185 cases and 143 controls. We identified over 1,300 antigenic T. cruzi peptides derived from 961 proteins between specimen sets. A total of 67 peptides were reactive in 70% of samples across all regions, and 3 peptide epitopes were enriched in ≥90% of seropositive samples. Of these three, only one antigen, belonging to the trans-sialidase family, has not previously been described as a diagnostic target. Orthogonal validation of this peptide demonstrated increased antibody reactivity for infections originating from Central America. Overall, this study provides proteome-wide identification of seroreactive T. cruzi peptides across a large cohort spanning multiple endemic areas and identified a novel trans-sialidase peptide antigen (TS-2.23) with significant potential for translation into diagnostic serological assays. One Sentence Summary: Phage display immunoprecipitation sequencing (PhIP-seq) designed with a T. cruzi whole proteome library reveals a trans-sialidase peptide antigen (TS-2.23) with antibody responses highly prevalent across endemic regions of Latin America.
Open AccessA Trypanosoma cruzi Trans-Sialidase Peptide Demonstrates High Serological Prevalence Among Infected Populations Across Endemic Regions of Latin America
Infection by Trypanosoma cruzi , the agent of Chagas disease, can irreparably damage the cardiac and gastrointestinal systems during decades of parasite persistence and related inflammation in these tissues. Diagnosis of chronic disease requires confirmation by multiple serological assays due to the imperfect performance of existing clinical tests. Current serology tests utilize antigens discovered over three decades ago with small specimen sets predominantly from South America, and lower test performance has been observed in patients who acquired T. cruzi infection in Central America and Mexico. Here, we attempt to address this gap by evaluating antibody responses against the entire T. cruzi proteome with phage display immunoprecipitation sequencing comprised of 228,127 47-amino acid peptides. We utilized diverse specimen sets from Mexico, Central America and South America, as well as different stages of cardiac disease severity, from 185 cases and 143 controls. We identified over 1,300 antigenic T. cruzi peptides derived from 961 proteins between specimen sets. A total of 67 peptides were reactive in 70% of samples across all regions, and 3 peptide epitopes were enriched in ≥90% of seropositive samples. Of these three, only one antigen, belonging to the trans-sialidase family, has not previously been described as a diagnostic target. Orthogonal validation of this peptide demonstrated increased antibody reactivity for infections originating from Central America. Overall, this study provides proteome-wide identification of seroreactive T. cruzi peptides across a large cohort spanning multiple endemic areas and identified a novel trans-sialidase peptide antigen (TS-2.23) with significant potential for translation into diagnostic serological assays. One Sentence Summary: Phage display immunoprecipitation sequencing (PhIP-seq) designed with a T. cruzi whole proteome library reveals a trans-sialidase peptide antigen (TS-2.23) with antibody responses highly prevalent across endemic regions of Latin America.
- Open Access
The Virtual Lab: AI Agents Design New SARS-CoV-2 Nanobodies with Experimental Validation
Science frequently benefits from teams of interdisciplinary researchers. However, most scientists don’t have access to experts from multiple fields. Fortunately, large language models (LLMs) have recently shown an impressive ability to aid researchers across diverse domains by answering scientific questions. Here, we expand the capabilities of LLMs for science by introducing the Virtual Lab, an AI-human research collaboration to perform sophisticated, interdisciplinary science research. The Virtual Lab consists of an LLM principal investigator agent guiding a team of LLM agents with different scientific backgrounds (e.g., a chemist agent, a computer scientist agent, a critic agent), with a human researcher providing high-level feedback. We design the Virtual Lab to conduct scientific research through a series of team meetings, where all the agents discuss a scientific agenda, and individual meetings, where an agent accomplishes a specific task. We demonstrate the power of the Virtual Lab by applying it to design nanobody binders to recent variants of SARS-CoV-2, which is a challenging, open-ended research problem that requires reasoning across diverse fields from biology to computer science. The Virtual Lab creates a novel computational nanobody design pipeline that incorporates ESM, AlphaFold-Multimer, and Rosetta and designs 92 new nanobodies. Experimental validation of those designs reveals a range of functional nanobodies with promising binding profiles across SARS-CoV-2 variants. In particular, two new nanobodies exhibit improved binding to the recent JN.1 or KP.3 variants of SARS-CoV-2 while maintaining strong binding to the ancestral viral spike protein, suggesting exciting candidates for further investigation. This demonstrates the ability of the Virtual Lab to rapidly make impactful, real-world scientific discovery.
Open AccessThe Virtual Lab: AI Agents Design New SARS-CoV-2 Nanobodies with Experimental Validation
Science frequently benefits from teams of interdisciplinary researchers. However, most scientists don’t have access to experts from multiple fields. Fortunately, large language models (LLMs) have recently shown an impressive ability to aid researchers across diverse domains by answering scientific questions. Here, we expand the capabilities of LLMs for science by introducing the Virtual Lab, an AI-human research collaboration to perform sophisticated, interdisciplinary science research. The Virtual Lab consists of an LLM principal investigator agent guiding a team of LLM agents with different scientific backgrounds (e.g., a chemist agent, a computer scientist agent, a critic agent), with a human researcher providing high-level feedback. We design the Virtual Lab to conduct scientific research through a series of team meetings, where all the agents discuss a scientific agenda, and individual meetings, where an agent accomplishes a specific task. We demonstrate the power of the Virtual Lab by applying it to design nanobody binders to recent variants of SARS-CoV-2, which is a challenging, open-ended research problem that requires reasoning across diverse fields from biology to computer science. The Virtual Lab creates a novel computational nanobody design pipeline that incorporates ESM, AlphaFold-Multimer, and Rosetta and designs 92 new nanobodies. Experimental validation of those designs reveals a range of functional nanobodies with promising binding profiles across SARS-CoV-2 variants. In particular, two new nanobodies exhibit improved binding to the recent JN.1 or KP.3 variants of SARS-CoV-2 while maintaining strong binding to the ancestral viral spike protein, suggesting exciting candidates for further investigation. This demonstrates the ability of the Virtual Lab to rapidly make impactful, real-world scientific discovery.
- Open Access
High-yield production of recombinant human myelin oligodendrocyte glycoprotein in SHuffle bacteria without a refolding step
1.1 Experimental autoimmune encephalomyelitis (EAE) is a model for central nervous system (CNS) autoimmune demyelinating diseases such as multiple sclerosis (MS) and MOG antibody-associated disease (MOGAD). Immunization with the extracellular domain of recombinant human MOG (rhMOG), which contains pathogenic antibody and T cell epitopes, induces B cell-dependent EAE for studies in mice. However, these studies have been hampered by rhMOG availability due to its insolubility when overexpressed in bacterial cells, and the requirement for inefficient denaturation and refolding. Here, we describe a new protocol for the high-yield production of soluble rhMOG in SHuffle cells, a commercially available E. coli strain engineered to facilitate disulfide bond formation in the cytoplasm. SHuffle cells can produce a soluble fraction of rhMOG yielding >100 mg/L. Analytical size exclusion chromatography multi-angle light scattering (SEC-MALS) and differential scanning fluorimetry of purified rhMOG reveals a homogeneous monomer with a high melting temperature, indicative of a well-folded protein. An in vitro proliferation assay establishes that purified rhMOG can be processed and recognized by T cells expressing a T cell receptor (TCR) specific for the immunodominant MOG 35-55 peptide epitope. Lastly, immunization of wild-type, but not B cell deficient, mice with rhMOG resulted in robust induction of EAE, indicating a B cell-dependent induction. Our SHuffle cell method greatly simplifies rhMOG production by combining the high yield and speed of bacterial cell expression with enhanced disulfide bond formation and folding, which will enable further investigation of B cell-dependent EAE and expand human research of MOG in CNS demyelinating diseases.
Open AccessHigh-yield production of recombinant human myelin oligodendrocyte glycoprotein in SHuffle bacteria without a refolding step
1.1 Experimental autoimmune encephalomyelitis (EAE) is a model for central nervous system (CNS) autoimmune demyelinating diseases such as multiple sclerosis (MS) and MOG antibody-associated disease (MOGAD). Immunization with the extracellular domain of recombinant human MOG (rhMOG), which contains pathogenic antibody and T cell epitopes, induces B cell-dependent EAE for studies in mice. However, these studies have been hampered by rhMOG availability due to its insolubility when overexpressed in bacterial cells, and the requirement for inefficient denaturation and refolding. Here, we describe a new protocol for the high-yield production of soluble rhMOG in SHuffle cells, a commercially available E. coli strain engineered to facilitate disulfide bond formation in the cytoplasm. SHuffle cells can produce a soluble fraction of rhMOG yielding >100 mg/L. Analytical size exclusion chromatography multi-angle light scattering (SEC-MALS) and differential scanning fluorimetry of purified rhMOG reveals a homogeneous monomer with a high melting temperature, indicative of a well-folded protein. An in vitro proliferation assay establishes that purified rhMOG can be processed and recognized by T cells expressing a T cell receptor (TCR) specific for the immunodominant MOG 35-55 peptide epitope. Lastly, immunization of wild-type, but not B cell deficient, mice with rhMOG resulted in robust induction of EAE, indicating a B cell-dependent induction. Our SHuffle cell method greatly simplifies rhMOG production by combining the high yield and speed of bacterial cell expression with enhanced disulfide bond formation and folding, which will enable further investigation of B cell-dependent EAE and expand human research of MOG in CNS demyelinating diseases.
- Open Access
Open-source milligram-scale, four channel, automated protein purification system
Liquid chromatography purification of multiple recombinant proteins, in parallel, could catalyze research and discovery if the processes are fast and approach the robustness of traditional, “one-protein-at-a-time” purification. Here, we report an automated, four channel chromatography platform that we have designed and validated for parallelized protein purification at milligram scales. The device can purify up to four proteins (each with its own single column), has inputs for up to eight buffers or solvents that can be directed to any of the four columns via a network of software-driven valves, and includes an automated fraction collector with ten positions for 1.5 or 5.0 mL collection tubes and four positions for 50 mL collection tubes for each column output. The control software can be accessed either via Python scripting, giving users full access to all steps of the purification process, or via a simple-to-navigate touch screen graphical user interface that does not require knowledge of the command line or any programming language. Using our instrument, we report milligram-scale, parallelized, single-column purification of a panel of mammalian cell expressed coronavirus (SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-229E) trimeric Spike and monomeric Receptor Binding Domain (RBD) antigens, and monoclonal antibodies targeting SARS-CoV-2 Spike (S) and Influenza Hemagglutinin (HA). We include a detailed hardware build guide, and have made the controlling software open source, to allow others to build and customize their own protein purifier systems.
Open AccessOpen-source milligram-scale, four channel, automated protein purification system
Liquid chromatography purification of multiple recombinant proteins, in parallel, could catalyze research and discovery if the processes are fast and approach the robustness of traditional, “one-protein-at-a-time” purification. Here, we report an automated, four channel chromatography platform that we have designed and validated for parallelized protein purification at milligram scales. The device can purify up to four proteins (each with its own single column), has inputs for up to eight buffers or solvents that can be directed to any of the four columns via a network of software-driven valves, and includes an automated fraction collector with ten positions for 1.5 or 5.0 mL collection tubes and four positions for 50 mL collection tubes for each column output. The control software can be accessed either via Python scripting, giving users full access to all steps of the purification process, or via a simple-to-navigate touch screen graphical user interface that does not require knowledge of the command line or any programming language. Using our instrument, we report milligram-scale, parallelized, single-column purification of a panel of mammalian cell expressed coronavirus (SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-229E) trimeric Spike and monomeric Receptor Binding Domain (RBD) antigens, and monoclonal antibodies targeting SARS-CoV-2 Spike (S) and Influenza Hemagglutinin (HA). We include a detailed hardware build guide, and have made the controlling software open source, to allow others to build and customize their own protein purifier systems.